• Explore /
  • Poster
  • / First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).

Abstract Poster

Authors

Jose Ruiz-Morales

Jose Manuel Ruiz Morales

Tom Baker Cancer Centre - University of Calgary, Calgary, AB, Canada

Jose Manuel Ruiz Morales , Marcin Swierkowski , Connor Wells , Anna Paola Fraccon , Francesca La Russa , Frede Donskov , Georg A. Bjarnason , Jae-Lyun Lee , Hao-Wen Sim , Benoit Beuselinck , Lori Wood , Takeshi Yuasa , Carmel Jo Pezaro , Brian I. Rini , Cezary Szczylik , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4510)

DOI

10.1200/JCO.2016.34.15_suppl.4510

Abstract #

4510

Poster Bd #

133

Abstract Disclosures

Similar Posters

First Author: Jose Manuel Ruiz Morales

Poster

2022 ASCO Genitourinary Cancers Symposium

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

First Author: Matthew Scott Ernst

First Author: Martin Boegemann

First Author: Ana-Alicia Beltran-Bless